EXPAREL

Pacira Pharmaceuticals, Inc.🇺🇸 United States

FDA Page

Effective Date: Nov 30, 2023
Approval ID: bb5a9e59-0f51-11df-8a39-0800200c9a66
Products: 2 registered
Version: 30

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use EXPAREL® safely and effectively. See full prescribing information for EXPAREL. EXPAREL (bupivacaine liposome injectable suspension), for infiltration or perineural use Initial U.S. Approval: 1972

Quick Stats

Total Products2

Labelers2

Label Sections23

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.